MB Therapeutics
MB Therapeutics is developing personalized 3D printed medications that offer customized dosages and improved drug administration, particularly for pediatric patients.
- CEO / Founder
- Stéphane Roulon
- Team Size
- 1-10
- Stage
- Active
- Total Funding
- $2.2M
- Latest Round
- Seed
- Key Investors
- Beprep, Calyseed, Angels Sante
Technology & Products
Key Products
MED-U Prod (industrial GMP/BPF pharmaceutical 3D printer for in-pharmacy oral solid forms) and MED-U Ink (ready-to-print pharmaceutical cartridges with CoA); co-developed and custom cartridge formulations for hospital pharmacies (PUI) and industrial labs.
Technological Advantage
Ability to produce customized dosages and integrate multiple drugs into a single pill.
Differentiation
Value Proposition
Customized drug dosages with improved administration enabled by 3D printing and GMP-certified manufacturing.
How They Differentiate
Focused on pediatric care and combining GMP-certified manufacturing with innovative 3D printing technology.
Market & Competition
Target Customers
Hospital pharmacies (PUI), compounding pharmacies, and pharmaceutical industrial/R&D labs (pediatric dosing remains a flagship use case)
Industry Verticals
Pharmaceuticals, Pediatric care
Competitors
Aprecia Pharmaceuticals; FabRx; Doser
Growth & Milestones
Growth Metrics
Raised €2 million in funding, led by Beprep, Calyseed, Angels Santé, BPI, and business angels including Sébastien Gallice. Plans to launch three high-demand medicines and pursue Series A funding in 2026. Supported by BIC 3M, AD'OCC region, and BPI.
Major Milestones
Expansion of leadership team with Damien Stefanelli as COO, Participation in GERPAC 2024 to showcase innovations, CHU de Nîmes innovation partnership for personalized 3D-printed meds (Jun 2025), VivaTech 2026 exhibition of pharma 3D printing platform (Jul 2026), Ian Soulairol (CSO) awarded Université de Montpellier / Métropole Innovation Prize 'Coup de Cœur' (Jul 2026)
Notable Customers
University Hospital Center of Nîmes; Sanofi